STUDY OF CLINICAL AND PATHOGENETIC EFFECTS OF ANTI-VIRAL DRUG BASED ON FAVIPIRAVIR IN COMORBID PATIENTS WITH COVID-19 AT THE OUTPATIENT STAGE OF TREATMENT

In many ways, arterial hypertension and obesity determine the likelihood of a severe course and lethal outcomes in COVID-19. This fact justifies the expediency of an early use of drugs with a direct antiviral action, the analysis of their efficacy not only in the acute, but also in the postcovid per...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: L. A. Balykova, O. A. Radaeva, K. Ya. Zaslavskaya, Yu. A. Kostina, M. S. Iskandyarova, E. V. Negodnova, V. V. Eremeev, L. F. Sabirov, E. V. Semeleva
Format: Artigo
Idioma:Russo
Publicat: Pyatigorsk Medical and Pharmaceutical Institute - branch of Volgograd State Medical University 2021-12-01
Col·lecció:Farmaciâ i Farmakologiâ (Pâtigorsk)
Matèries:
favipiravir
covid-19
novel coronavirus infection
areplivir
Accés en línia:https://www.pharmpharm.ru/jour/article/view/981
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars